Treatment

MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA

Retrieved on: 
Friday, February 23, 2024

AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases.

Key Points: 
  • AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases.
  • Fasenra met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA).
  • Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States.
  • A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (NATRON).

Clinical Review of Pegylated Interferons Suggests Formulation and Mechanism of Action May Improve Outcomes for MPN Patients

Retrieved on: 
Wednesday, February 21, 2024

The manuscript, "Interferons in the Treatment of Myeloproliferative Neoplasms” was co-authored by 12 renowned myeloproliferative neoplasm (MPN) specialists and published in Therapeutic Advances in Hematology .

Key Points: 
  • The manuscript, "Interferons in the Treatment of Myeloproliferative Neoplasms” was co-authored by 12 renowned myeloproliferative neoplasm (MPN) specialists and published in Therapeutic Advances in Hematology .
  • Writing and editorial support were funded by PharmaEssentia, however authors retained full editorial control and provided final approval on all content.
  • “Interferons are immune modulators that have been used to treat MPNs for more than 35 years.
  • “This review will continue to help the greater medical community better understand the potential of interferons, as well as potential dosing regimens and combination therapies for patients,” said Albert Qin, M.D., Ph.D., Chief Medical Officer, PharmaEssentia.

Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

Retrieved on: 
Tuesday, February 20, 2024

The manuscript, “First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer,” has been published in the Journal of Nuclear Medicine (DOI https://doi.org/10.2967/jnumed.123.266741 ).

Key Points: 
  • The manuscript, “First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer,” has been published in the Journal of Nuclear Medicine (DOI https://doi.org/10.2967/jnumed.123.266741 ).
  • In the 4 consecutive patients with metastatic prostate cancer who were evaluated, when looking at radiologic progression free survival (rPFS), 2 patients had not progressed at 24 and 18 months of follow-up.
  • 177Lu-rhPSMA-10.1 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted radiopharmaceutical for the treatment of prostate cancer, and the lead candidate in Blue Earth Therapeutics’ development of next generation therapeutic radiopharmaceuticals.
  • “These promising clinical data give us further optimism in advancing 177Lu-rhPSMA forward in clinical development, with the hope to help treat patients with metastatic prostate cancer.

Global Clear Aligner Market Analysis and Forecast to 2029: Compound Annual Growth of 22% Forecast During 2024-2029, Driven by Growing Patient Population Suffering from Malocclusions - ResearchAndMarkets.com

Retrieved on: 
Monday, February 19, 2024

The global clear aligner market was valued at US$5.56 billion in 2023.

Key Points: 
  • The global clear aligner market was valued at US$5.56 billion in 2023.
  • An increase in the incidence of periodontitis would support the growth of the clear aligner market in Europe.
  • The rising prevalence of malocclusion cases is positively affecting the demand for the clear aligner and hence, boosting the market growth.
  • Thus, the growing dental tourism is expected to stimulate the demand for clear aligners in the coming years.

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer

Retrieved on: 
Monday, February 19, 2024

AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy.

Key Points: 
  • AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy.
  • In patients with nonsquamous NSCLC, datopotamab deruxtecan showed a clinically meaningful PFS benefit and a numerically favorable OS trend.
  • Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Datopotamab deruxtecan has the potential to offer patients with previously treated advanced nonsquamous non-small cell lung cancer an effective and tolerable alternative to conventional chemotherapy.
  • Additional regulatory submissions for datopotamab deruxtecan in lung and breast cancer are underway globally.

EMA and European Organisation for Research and Treatment of Cancer (EORTC) workshop: How can patient-reported outcomes (PRO) and health-related quality of life (HRQoL) data inform regulatory decisions?, Online, European Medicines Agency, Amsterdam, t[...]

Retrieved on: 
Sunday, March 10, 2024

This workshop will bring together international experts from academia, learned societies, patients, regulatory agencies, health technology assessment bodies, and industry.

Key Points: 
  • This workshop will bring together international experts from academia, learned societies, patients, regulatory agencies, health technology assessment bodies, and industry.
  • The aims of the workshop are to:
    - Understand the current global landscape on the use of PROs and HRQOL for evaluation of anti-cancer treatments across different stakeholder groups.
  • - Understand the use of validated PRO questionnaires to measure core HRQOL outcomes and disease-related symptoms; and PRO Item Libraries in the development of trial-specific/treatment-specific item lists.
  • The recording of this meeting will be made available after the event.

Cancer Medicines Forum workshop: April 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 5 April 2024, 13:00 (CEST) to 5 April 2024, 18:00 (CEST)

Retrieved on: 
Sunday, March 10, 2024

The deliverables of the CMF are aimed at supporting policy decisions to facilitate treatment optimisation in Europe with a focus on post-licensing questions based on clinically relevant end-points for patients in the healthcare setting.

Key Points: 
  • The deliverables of the CMF are aimed at supporting policy decisions to facilitate treatment optimisation in Europe with a focus on post-licensing questions based on clinically relevant end-points for patients in the healthcare setting.
  • Registration
    You can register to the workshop at the following link:
    Registration will close on 1 March 2024 for in-person participation.
  • In-person participation will be confirmed by 8 March 2024 and will be based on the capacity of the venue and distribution amongst several stakeholders.
  • Video recording
    The workshop will be broadcast live and a recording of this meeting will be made available after the event.

Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Retrieved on: 
Wednesday, March 6, 2024

These findings were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) held in Florence, Italy, on March 6, 2024.

Key Points: 
  • These findings were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) held in Florence, Italy, on March 6, 2024.
  • GLP-1 medicines – also known as glucagon-like peptide-1 receptor agonist (GLP-1 RA) - are increasingly being prescribed for people with Type 2 diabetes as they provide glycemic benefit and support weight loss.
  • "While treating my patients, I've observed that when we've added a CGM, like the FreeStyle Libre technology, to their GLP-1 therapy, we see even better glycemic control.
  • To maximize the benefits of GLP-1 medicines, it's worth considering the combination of a CGM to support people who live with Type 2 diabetes."

Global Cardiology IT Workflow Solutions Research Report 2022-2024 and 2030 - Launch of New and Revamped Platforms Bodes Well for Market Growth

Retrieved on: 
Saturday, March 2, 2024

DUBLIN, March 1, 2024 /PRNewswire/ -- The "Cardiology IT Workflow Solutions - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 1, 2024 /PRNewswire/ -- The "Cardiology IT Workflow Solutions - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Cardiology IT Workflow Solutions estimated at US$969 Million in the year 2022, is projected to reach a revised size of US$1.8 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2022-2030.
  • Cardiology IT workflow solutions have seen a significant rise in adoption, driven by the increasing reliance on IT for managing patient data in cardiology departments globally.
  • As the healthcare industry continues to evolve, especially in the post-COVID-19 period, the cardiology IT workflow solutions market is expected to witness continued growth and innovation.

Limb-Girdle Muscular Dystrophy Leaders Advance Collaborative Dialogue to Accelerate Drug Development to Address the Urgent Unmet Need in Limb-Girdle Muscular Dystrophy

Retrieved on: 
Tuesday, February 27, 2024

The meeting focused on six LGMD subtypes: 2A/R1, 2B/R2, 2C/R5, 2D/R3, 2E/R4, and 2I/R9.

Key Points: 
  • The meeting focused on six LGMD subtypes: 2A/R1, 2B/R2, 2C/R5, 2D/R3, 2E/R4, and 2I/R9.
  • We are thrilled that the workshop advanced a collaborative dialogue and brought people together from every facet of the drug development process to drive progress for patients.
  • This was truly a monumental event for the LGMD community and a model for others to follow in the future."
  • In-depth documentation of the workshop's findings and next steps is in progress and will be shared when available.